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Background: Pendred syndrome is a common autosomal recessive disorder causing deafness. Features include
sensorineural hearing impairment, goitre, enlarged vestibular aqueducts (EVA) and occasionally Mondini dysplasia.
Hearing impairment and EVA may occur in the absence of goitre or thyroid dyshormonogensis in a condition
known as non-syndromic EVA. A significant number of patients with Pendred syndrome and non-syndromic EVA
show only one mutation in SLC26A4. Two genes, KCNJ10, encoding an inwardly rectifying potassium channel and
FOXI1, a transcriptional factor gene, are thought to play a role in the disease phenotypes.
Methods: Using Polymerase Chain Reaction and Sanger sequencing, sixty-eight patients with monoallelic
mutations of SLC26A4 were tested for mutations in KCNJ10 and FOXI1.
Results: Two variants were observed in the KCNJ10 gene, p.Arg271Cys in three patients and p.Arg18Gln in one
patient; only one variant, p.Arg123Trp was observed in the FOXI1 gene in a single patient. Both p.Arg271Cys and p.
Arg18Gln are likely to be polymorphisms as judged by their frequency in the general population.
Conclusion: Therefore we found no evidence for a significant association between mutations of KCNJ10 and FOXI1
with SLC26A4. It was also observed that the variant, p.Arg271Cys in KCNJ10, previously thought to have a protective
effect against seizure susceptibility, was found in a patient with Pendred syndrome with co-existing epilepsy.
Keywords: Deafness, Enlarged vestibular aqueducts, Epilepsy, EVAS, FOXI1, Hearing impairment, KCNJ10, Pendred
syndrome, SLC26A4Background
Pendred syndrome (PDS) (OMIM 274600) is one of the
most common autosomal recessive disorders of hearing
[1,2], characterised by mild to severe sensorineural hearing
impairment (SNHL) [2-5] goitre, and inner ear malforma-
tions, typically an enlargement of the vestibular aqueduct
(EVA) [6]. Some PDS cases can also exhibit Mondini
dysplasia which involves the bilateral enlargement of the
vestibular aqueducts (EVA) with cochlear hypoplasia [7].
EVA can also be associated with other forms of syndromic
and non-syndromic deafness (DFBN4 (OMIM 600791))* Correspondence: maria.bitner@ucl.ac.uk
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aqueducts.
Pendred syndrome is the result of malfunction in
pendrin, an apical protein anion transporter which medi-
ates chloride (Cl-), hydroxide (OH-), bicarbonate (HCO3-)
and iodide (I-) exchange [10,11]. Pendrin is expressed in
the thyroid and importantly, in the inner ear to maintain
the endocochlear potential [5] as well as in the kidney.
Dysfunction of ion transport affects iodide organification
for thyroid hormone biosynthesis [4] resulting in goitre
[1,3,12], which distinguishes it from non-syndromic EVA.
However, the majority of patients remain euthyroid [13].
It is now widely acknowledged that mutations in the gene
SLC26A4 located on chromosome 7q21-34 [14,15] are
involved in the presentation of an EVA/PDS phenotype
[14,16,17]. Biallelic mutations in the gene SLC26A4 have
been shown to cause Pendred syndrome, accounting fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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there is evidence to show that a cohort of patients affected
by hearing loss and EVA, have only one mutant allele of
SCL26A4; Yang et al. showed that in patients with hearing
loss and EVA, in whom thyroid disorder was not used as a
clinical criterion, 19% of siblings had a single mutation in
SLC26A4 and 42% had zero mutations, suggesting that
other genetic factors may be involved [19] in the aetiology
of their hearing loss. Rendtorff et al., in a clinically well-
phenotyped cohort of 109 Scandinavian patients, showed
that 10% had monoallelic mutations. Likely heterogeneity
of PDS and non-syndromic EVA has been proposed and
investigated, with some suggesting a complex relationship
between heterozygosity and the severity of the EVA/PDS
phenotype [20].
Two genes, KCNJ10 and FOXI1, have been investi-
gated for their role in the PDS disease spectrum and it
has been proposed that digenic mutations in both
SLC26A4 and either FOXI1 or KCNJ10 may cause
Pendred syndrome [19,21]. The gene KCNJ10 encodes
an inwardly rectifying potassium (K+) channel, namely
the Kir4.1 channel, expressed in a wide variety of tissues
but most importantly in the case of Pendred syndrome,
in the cochlear stria vascularis which maintains the
endocochlear potential and K + homeostasis [22-24]. It
has been shown that mice models that lacked the
Slc26a4 gene (Slc26a4−/−) did not express Kcnj10 and
that lack of this protein led to the loss of the endoco-
chlear potential via endolymphatic acidification and Ca2+
absorption inhibition [25,26] which may be the direct
cause of deafness in Pendred syndrome. Variants of
KCNJ10 have also been considered as a risk factor for
seizure susceptibility in genetic association studies [27]
and biallelic mutations in KCNJ10 in humans are known
to cause a syndromic form of hearing loss, EAST syn-
drome (epilepsy, ataxia, sensorineural deafness and renal
tubulopathy) [28].
FOXI1 is a transcription factor gene and an upstream
regulator of SCL26A4 [19,29]. It is also involved in the
regulation of vascular H+-ATPase proton pumps in the
inner ear, epididymis and kidney [30]. It was proposed
that digenic inheritance of mutations in both FOXI1 and
SLC26A4 were involved in the genetic basis of Pendred
syndrome, as mutations in FOX1 were shown to reduce
the transcription of SLC26A4 [19]. Moreover, Foxi1 null
mice showed phenotypic features of sensorineural deaf-
ness due to the defective pendrin-chloride mediated
reabsorption in which FOXI1 was most likely a key regu-
lator [29].
Only a few studies have found evidence that KCNJ10
or FOXI1 gene mutations may influence the disease
phenotype shown in patients with monoallelic mutations
in the SLC26A4 gene. The present study investigates
whether variants in KCNJ10 and FOXI1 in combinationwith heterozygosity for SLC26A4 mutations are likely to
be associated with the disease phenotype seen in
Pendred syndrome/EVA patients (who already have one
mutation in the SLC26A4 gene). Because of the sug-
gested role of KCNJ10 in both epilepsy and PDS/EVA,
we also screened 3 unrelated patients with the combin-
ation of Pendred syndrome and seizures.
Methods
Clinical and molecular evaluation of subjects
68 patient samples were referred for screening of
SLC26A4 because of a history of hearing impairment and
either goitre or EVA. Available clinical details are given in
Additional file 1. All patients gave informed consent for
genetic testing for diagnosis of their deafness. All were
referred for genetic testing by Clinical Geneticists,
Genetic Counsellors or Paediatricians. A further 3
patients with Pendred syndrome (who had bi-allelic
SLC26A4 mutations), who had a clinical history of seizu-
res, were also screened for specific variants in KCNJ10/
FOXI1. In addition 95 pan-ethnic controls were sequenced
for FOXI1.
Genetic analyses
Genomic DNA was extracted from whole blood to stand-
ard using Flexigene (Qiagen) chemistry on the Autogen
Flex (Autogen) or, where samples were received from
other NHS hospitals, were extracted using their normal
protocols. Polymerase chain reaction (PCR) was perfor-
med on all samples with a total reaction volume of 20 μL
consisting of 0.5 μL genomic DNA, 19 μL Megamixmix
(Microzone Ltd) and 0.5 μL of forward and reverse tailed
primers for each gene. All 3 KCNJ10 exons were amplified
using the peltier thermal cycler (Biorad tetrad 2 DNA
engine) and PCR was performed under the following PCR
conditions: incubation at 95°C for 2 mins followed by 32
cycles of denaturation at 95°C for 30 seconds, annealing at
62°C for 30 seconds and an extension at 72°C for 30
seconds followed by a final 2mins at 72°C. All 4 FOXI1
exons were amplified with the same process but with the
following touchdown PCR conditions: 95°C for 2 mins
followed by 95°C for 30 seconds, 65°C for 30 seconds and
72°C for 30 seconds, decreasing the annealing tempera-
ture by 1°C for a further 14 cycles then 95°C for 30
seconds, 50°C for 30 seconds and 72°C for 30 seconds for
a further 19 cycles followed by a final 2 mins at 72°C.
Primers
Primers were designed using bioinformatics software,
Primer3 (v4) (http://primer3.wi.mit.edu/). No SNPs were
found using SNPCheckV3 (https://ngrl.manchester.ac.
uk/SNPCheckV3/snpcheck.htm;jsessionid=1D413B67748
713D5A68E85D95C00D87C, NGRL Manchester).
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Sanger sequencing. All forward and reverse primers
were tailed at the 5′ of the primer (Table 1).
Sequencing of PCR products
The complete coding regions and splice sites of the
KCNJ10 and FOXI1 exons were subjected to bidirectional
sequencing using ABI PRISM Big Dye Terminator cycle
sequencing ready reaction kit (Applied Biosystems) and
analysed on an ABI3730 Genetic Analyser (Applied
Biosystems) using standard protocols. The data was col-
lated using Foundation Data Collection v3.0 and were
analysed using the software program Mutation Surveyor
v.3.30 (Softgenetics) and in comparison to the GenBank
sequences of KCNJ10 (Genomic reference: NM_002241.4)
and FOXI1 (Genomic reference: NM_012188.4). The data
was also analysed for reported variants within the gene by
using Alamut (Interactive Biosoftware).
Results
Screening of FOXI1 and KCNJ10 was completed for the
cohort of 68 patients all of whom had previously been
found to have only a single mutation in the SLC26A4 gene.
Results are shown in Table 2. In KCNJ10, three unrelated
patients were identified with the variant p.Arg271Cys
(c.811C > T) and one with p.Arg18Gln (c.52G >A). In
FOXI1, only one patient was observed to have a variant,
p.Arg123Trp (c.367C > T). This variant was not found
in the 95 pan-ethnic controls. No other mutations in
either KCNJ10 or FOXI1 were found.
Results of the analysis of the three further patients
referred for SLC26A4 screening who also had a history
of seizures are shown in Table 3. One patient was found
to have p.Arg271Cys, and one had the variant p.Arg18Gln.
Discussion
The evidence that genetic factors in addition to mutations
in the coding region of the SLC26A4 gene contribute to
Pendred syndrome and non-syndromic EVA has origi-
nated from both mouse and human studies. In humansTable 1 Primers used to screen KCNJ10 and FOXI1
Gene Exon Forward
KCNJ10 2A GGCACAT
2B TGGTGTG
2C ACCCCTTA
FOXI1 1A GCCAAGC
1B CAGGCCT
2A GCCTGTC
2C CATCTTGG
Tail AGCTAAGthe most compelling fact is that bi-allelic SLC26A4 muta-
tions are found in only a minority of patients, even those
with the most severe phenotype of EVA-Mondini and thy-
roid dysfunction or goitre. Undiscovered non-coding re-
gion mutations of SLC26A4 are unlikely to fully explain
this observation as a number of groups have performed
extensive analysis of non-coding regions with little yield,
although a variant in the promoter region of SLC26A4
which binds the transcription factor, FOXI1 was noted.
Furthermore, siblings with discordant phenotypes, a
mono-allelic SLC26A4 mutation and concordant SLC26A4
haplotypes, as well as siblings with concordant phenotypes
but discordant haplotypes, indicate evidence for locus
heterogeneity [9].
Studies based on mouse models
Studies in mice have suggested other genes that might
influence the PDS/EVA phenotype and may act in a
digenic, or additive manner. Mice lacking FOXI1 are
deaf, have inner ear malformations (EVA and cochlear
dysplasia) as well as renal tubular acidosis and male
infertility. Furthermore these mice show no expression
of SLC26A4 in the inner ear, implying that as an up-
stream regulator, FoxI1 expression is necessary for the
transcription of Slc26a4. Therefore the contribution of
FOXI1 to EVA/PDS was investigated in humans by Yang
et al., who found a variant in the promoter of SLC26A4
in a consensus binding motif for FOXI1, c.-101T > C;
they showed using EMSAs that binding affinity of
FOXI1 to the promoter was reduced in the presence of
c.-101T > C and used Luciferase reporter constructs to
show that transcription from the promoter was com-
pletely abolished in the presence of this variant [19]. Fur-
ther screening of the coding region of FOXI1 itself revealed
five further non-synonymous variants, p. Asp161del, p.
Arg267Gln, p.Gly335Val, p.Gly258Arg, p.Gly258Glu among
372 probands with EVA in whom one or zero SLC26A4
mutations had previously been found. All five mu-
tations showed reduced activation of the luciferase
reporter construct. Finally mice which are doubleprimer Reverse primer
AGCAAGTGCTCAA AGATTTCCAGGATGGTGGTG
GTATCTGGTAGCTG CAAAGTCACCCTCACCACTG
CCTTCTATCATG GTAGTATTCCTTACCAGGGC
CCTAGGGGTATAA AGCTTCATCAGCTCCTCCTG
ATGGAGTGCAGA CCATGCTCTCCTTCACTGCT
GGTCTCTGTCTTC CTCAGTCCTGGTGTGACCAA
ATGGAGCCTCAC CCTGCTTATGTCTGGGCAGT
CGCGAGAAGGC AGCTAAGCGCGAGAAGGC
Table 2 KCNJ10 and FOXI1 mutations identified in patients with monoallelic mutations in SLC26A4
Patient SLC26A4 mutation (cDNA) SLC26A4 mutation (protein) FOXI1 Variant KCNJ10 Variant
25215 c.1001 + 1G > A N N
25278 c.1790T > C p.Leu597Ser N N
34515 c.716T > A p. Val239Asp N N
28979 c.1061T > C p.Phe354Ser N N
35265 c.707T > C p.Leu236Pro N N
40257 c.1001 + 1G > A N N
37952 c.1151A > G p.Glu384Gly N N
38201 c.1790T > C p.Leu597Ser N N
42836 c.707T > C p.Leu236Pro N N
42564 (c.1234G > A p.Val412Ile) N N
41066 c.1001 + 1G > A N N
40187 c.412G > T p.Val138Phe N N
44595 c.2127delT p.Phe709Leufs*12 N c.811C > T (p.Arg271Cys)/N
45381 c.1790T > C p.Leu597Ser N N
13343 c.1342-2_1343dup p.Leu450Glyfs*19 N N
45592 c.340G > A p.Gly114Arg N N
48799 c.1001 + 1G > A N N
46182 c.707T > C p.Leu236Pro N N
50939 c.2190G > T p.Gln730His N N
51079 c.707T > C p.Leu236Pro N N
54165 c.2T > C p.Met1? N N
59858 c.2080T > C p.Ser694Pro N N
61452 c.412G > T p.Val138Phe N N
54483 c.1790T > C p.Leu597Ser N N
63420 c.1151A > G p.Glu384Gly N N
65983 c.1211C > T p.Thr404Ile N N
50886 c.1151A > G p.Glu384Gly N N
66609 c.-3-2A > G N N
66643 c.[1001 + 1G > A(;) 2219C > T] (p.Gly740Val) N N
66830 c.1790T > C p.Leu597Ser N N
69863 c.113T > C p.Phe335Leu N N
47141 c.1790T > C p.Leu597Ser N N
72446 c.-3-2A > G N N
72770 c.412G > T p.Val138Phe N N
72617 c.1151A > G p.Glu384Gly N N
76349 c.1790T > C p.Leu597Ser N N
76715 c.1826T > G p.Val609Gly N N
78124 c.1468A > C p.Ile490Leu N N
78231 c.1001 + 1G > A N N
23853 c.2T > C p.Met1? N N
71753 c.1342-2_1343dup p.Leu450Glyfs*19 N N
72950 c.1229C > T p.Thr410Met N N
79945 (c.2219C > T) (p.Gly740Val) c.367C > T(p.Arg123Trp) N
80435 c.707T > C p.Leu236Pro N N
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Table 2 KCNJ10 and FOXI1 mutations identified in patients with monoallelic mutations in SLC26A4 (Continued)
10576 c.[1343C > T]; [1991C > T] p.[Ser448Leu]; [Ala664Ser] N N
83112 c.1790T > C p.Leu597Ser N N
84175 c.119delT (c.918G > A) p.Leu40ArgfsX26 N N
86297 c.2153G > T p.Phe718Ser N c.53G > A (p.Arg18Gln)/N
86482 c.707T > C p.Leu236Pro N N
85020 c.1234G > T p.Gln421Arg N N
83883 c.1790T > C p. Leu597Ser N N
87823 c.1790T > C p. Leu597Ser N N
84236 (c.73C > T) (p.Pro25Ser) N N
88933 c.1151A > G p.Glu384Gly N N
89770 c.1001 + 1G > A N N
90473 c.1790T > C p.Leu597Ser N c.811C > T (p.Arg271Cys) /N
90511 c.1003T > C p.Phe335Leu N c.811C > T (p.Arg271Cys) /N
90643 (c.970A > T) (p.Asn324Tyr) N N
91820 c.1790T > C p.Leu597Ser N N
40013 c.1000G > T p.Gly334Trp N N
89620 c.[1790T > C(;) 412G > T] p.[Val138Phe(;) (Leu597Ser)] N N
94065 c.1342-2_1343dup p.Leu450Glyfs*19 N N
89792 c.-103T > C N N
94743 c.1003T > C p.Phe335Leu N N
96669 c.2015G > A p.Gly672Glu N N
95020 c.1363A > T p.Ile455Phe N N
99311 c.626G > T p.Gly209Val N N
99458 c.1334T > G p.Leu445Trp N N
Unclassified variants are denoted in brackets. p.Leu597Ser may be a benign polymorphism or hypofunctional variant [39].
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Foxi1+/−) were reported to have EVA although hearing of
these mice was not commented on [19].
The potential role of the inwardly rectifying potassium
channel KCNJ10 in PDS/EVA was also suggested from
studies in mice. The Slc26a4−/− mouse is deaf and has
EVA and shows loss of endocochlear potential and no
expression of KCNJ10 protein in the stria vascularis.
KCNJ10 is thought to be crucial in the generation and
maintenance of the endocochlear potential necessary for
auditory transduction. In 2 out of 89 EVA/PDS patients
who were heterozygous for a single pathogenic SLC26A4
mutation, Yang et al. found two heterozygous mutations
in KCNJ10 in unrelated probands, and suggested a pro-
bable digenic interaction between these two genes. InTable 3 Patients with biallelic mutations of SLC26A4 tested fo
Patient SLC26A4 allele 1 SLC26A4 allele
66119 c.1229C > T p.Thr410Met c.1229C > T p.Th
5472 c.707T > C p.Leu236Pro c.626G > T p.Gly
6401 c.707T > C p.Leu236Pro c.707T > C p.Leutheir hands, expression of mutant KCNJ10 in Xenopus
oocytes showed markedly reduced K+ conductance [21].
Studies in humans
However subsequent work by others has shown that
recessive mutations in KCNJ10 do indeed cause hearing
loss, but as part of a complex syndrome, EAST syn-
drome, consisting of Epilepsy, Ataxia, Sensorineural
deafness and renal Tubulopathy. Heterozygote parents
are unaffected. In addition KCNJ10 has also been consi-
dered as a ‘susceptibility gene’ for epilepsy in humans.
However the variant p.Arg271Cys was thought to be a
protective allele against focal or generalised epilepsy
[22,31,32] and yet this was found in one of our patients
with co-existing seizures and Pendred syndrome. Asr variants within the KCNJ10 gene
2 KCNJ10 variant dbSNP
r410Met c.811C > T p.Arg271Cys rs1130183
209Val c.53G > A p.Arg18Gln rs115466046
236Pro N
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on channels, and because this variant is present in 563
of 8037 individuals (0.07) of European American des-
cent in Exome Variant Server (http://evs.gs.washington.
edu/EVS/), p.Arg271Cys is most likely to be a polymor-
phism, unrelated to either EVA/PDS or even epilepsy.
Similarly, the variant p.Arg18Gln has also been reported
previously, but in a single patient with autistic spectrum
disorder, seizures and intellectual disability but no deaf-
ness [33]. This suggests that it may be unrelated to any of
these phenotypes, consistent with its frequency in the
population (present in 1 in 57 European Americans in
EVS (148 in 8452 European Americans (0.0175)) (http://
evs.gs.washington.edu/EVS/). As the variant in FOXI1, p.
Arg123Trp (c.367C > T) has not been found at a high fre-
quency previously or in controls screened here, we cannot
be sure whether this is, or is not, a pathogenic mutation.
However it appears that mutations in FOXI1 are not a
major contributor to digenic inheritance in these cases.
Other genetic studies of patients with EVA/PDS have
failed to find convincing evidence that mutations of
FOXI1 and KCNJ10 contribute to these phenotypes.
Chen et al. [34] screened SLC26A4, FOXI1 and KCNJ10
(as well as GJB2) in patients with bilateral deafness and
inner ear malformations and found no mutations in
FOXI1 or KCNJ10 in the 15 who had one or zero
SLC26A4 mutations; Mercer et al. [35] screened 51
patients with EVA and found no mutations in FOXI1 or
KCNJ10; Jonard et al. [36] screened 25 patients with uni-
lateral deafness and unilateral EVA but found no muta-
tions in either KCNJ10 or FOXI1 and Wu et al. screened
FOXI1 in 100 patients with EVA and found no mutations,
although KCNJ10 was not screened at that time [37].
Cirello et al. did however find a novel missense variant in
FOXI1 p.Pro239Leu, and 3 patients with the variant p.
Arg271Cys in KCNJ10 out of 19 patients with PDS/EVA,
but functional analysis of p.Pro239Leu showed no sig-
nificant impairment in the transcriptional activation of
SLC26A4, and, p.Arg271Cys was classified as poly-
morphism [38].
Our study is the largest study to screen both KCNJ10
and FOXI1 in patients who were heterozygous for a
single SLC26A4 mutation in whom the promoter vari-
ant/FOXI1 (c.-101T > C) binding site had already been
excluded. Our results indicate that heterozygosity for
mutations in either of these genes in combination with a
heterozygous SLC26A4 mutation is not a significant
contributor to PDS/EVA in our cohort, even though
previous in vitro work and mouse studies suggest their
involvement in these phenotypes. The best evidence for
a possible functional role of either KCNJ10 or FOXI1 in
the PDS/EVA phenotype in humans would be genetic
evidence - further families with mutations, which are
shown to have a functional effect and which are presentin a lower frequency in the general population than
those with the PDS/EVA phenotype. Hopefully, NGS data
from large sequencing efforts such as 1000 Genomes and
EVS will be helpful in this respect.
It is possible that some of the cases presented here
could be ‘co-incidental’ carriers for mutations in SLC26A4
which do not contribute to their phenotype of hearing
loss, or that we could have missed single or multiple exon
deletions. However we think that this is unlikely to
account for a significant proportion of these cases. Renorff
et al. found no deletions in their series of patients sugges-
ting that deletions account for a very small number of
mutations in SLC26A4 [39]. Regarding carrier ship, we
have recently performed an audit of all requests for
SLC26A4 screening performed in our laboratory from
2002 onwards. This shows that where testing of SLC26A4
was requested, 66 out of a total of 538 patients tested,
had monoallelic mutations (ie. 1 in 8). Even if those with
variants of unknown significance are excluded, the hetero-
zygote carriership rate for SLC26A4 mutations would be
almost 4 times that for GJB2, the commonest form of
inherited deafness [40]. This suggests that heterozygosity
for SLC26A4 mutations is important in the aetiology of
the hearing loss in these patients.
Conclusion
This study combined with others, suggests that variants in
KCNJ10 and FOXI1 are not a major contributor to PDS/
EVA and that screening of these genes in a diagnostic
setting will add little information to genetic aetiology.
Other factors, genetic or environmental, are likely to play
a greater role in the aetiology of PDS/EVA.
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